CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced it has entered into a collaboration and supply agreement with BeiGene, Ltd. (to be changed to BeOne Medicines, ...
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2 nd - and 3 rd-line ...
On Feb. 18, 2026, investors weighed ImmunityBio’s EU bladder cancer win against its long slide since IPO and fresh legal scrutiny.
The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (IBRX) (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA (nogapendekin alfa inbakicept) ...
ImmunityBio, Inc. (NASDAQ:IBRX) shares are trading higher Friday after the company announced overall survival results in its QUILT 3.055 study. ImmunityBio said the QUILT 3.055 trial shows median ...
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. If you are wondering whether ImmunityBio's current share price is giving you a fair deal or ...
SAN FRANCISCO, Nov. 19, 2024 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises ImmunityBio, Inc. investors that the firm is investigating potential legal claims relating to the company's ...
Oral presentation provides update from QUILT-3.032 on durable complete responses to ANKTIVA® plus BCG in BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS) with or ...
ImmunityBio, Inc. (NASDAQ:IBRX) on Monday received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for the supplemental biologics license application (sBLA) for use of ...
Shares in ImmunityBio rose sharply after the company said it has agreed a path with the FDA that will allow it to refile for approval of wider use of its bladder cancer therapy, Anktiva, in ...
Pharmaceutical drugs developed by two local companies received approvals in the European Union last month. On Dec. 12, Culver City-based ImmunityBio Inc. announced that the European Medicines Agency, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results